Drupal.behaviors.print = function(context) {window.print();window.close();}>
Rosetta to Offer $35M in Public Offering, Receives NYS Approval for Lung Cancer Assay
June 26, 2012
Rosetta to Offer $35M in Public Offering, Receives NYS Approval for Lung Cancer Assay
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
New York Gives Final Approval for Rosetta Genomics' miRview Lung Assay
November 6, 2012 / GenomeWeb Daily News
Underwriters Exercise Option on Rosetta Public Offering; Total Gross Proceeds Rise to $31.6M
August 29, 2012 / GenomeWeb Daily News
Rosetta Genomics Closes on Public Offering, Raises $27.5M
August 8, 2012 / GenomeWeb Daily News
Rosetta Publishes Data on microRNA-Based Lung Cancer Assay
July 5, 2012 / Gene Silencing News
Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News